Suppr超能文献

细胞因子、趋化因子及趋化因子受体在卵巢癌患者中的定量表达

Cytokines, chemokines, and chemokine receptors quantitative expressions in patients with ovarian cancer.

作者信息

Rezaeifard Somayeh, Razmkhah Mahboobeh, Robati Minoo, Momtahan Mozhdeh, Ghaderi Abbas

机构信息

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; ; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;

出版信息

Iran J Med Sci. 2015 May;40(3):225-32.

Abstract

BACKGROUND

Cytokines, chemokines, and chemokine receptors regulate the proliferation and survival of tumor cells, angiogenesis, and metastasis to other organs. This network of ligands and receptors has been used in molecular targeting of cancer.

METHODS

We compared the mRNA expression of CXCR3, CXCL-10, CXCR4, CXCL-12, IL-4, and IL-10 in tissues of benign and malignant ovarian tumors by qRT-PCR method and evaluated serum IL-10 and CA-125 content of these patients by ELISA during one year.

RESULTS

Our result showed a trend toward a higher expression of CXCR4 in malignant ovarian tissues compared with the benign ovarian cysts (P>0.05). However, SDF-1, IP-10, IL-4, CXCR3, and IL-10 had a lower trend in mRNA expression in malignant ovarian tissues compared to the benign cyst tissues. Except for IL-4 (P=0.01) and SDF-1 (P=0.02), the data for other factors were not statistically significant. A trend toward higher concentration of IL-10 was observed in the serum of ovarian cancer patients compared to those with benign cysts; however, the difference was not significant. CA-125 concentration in the serum of ovarian cancer patients was higher than that of benign cyst patients (P=0.05).

CONCLUSION

According to results obtained, we hypothesize that the lower expression of SDF-1 in malignant tissues may have an important role in ovarian tumor growth. However, this hypothesis requires more investigation. Higher levels of CA125 and IL-10 in the serum of patients might indicate that the combination of these biomarkers could be used for distinguishing patients with ovarian cancer from those with benign cysts.

摘要

背景

细胞因子、趋化因子及趋化因子受体可调节肿瘤细胞的增殖与存活、血管生成以及向其他器官的转移。该配体和受体网络已被用于癌症的分子靶向治疗。

方法

我们采用qRT-PCR法比较了良性和恶性卵巢肿瘤组织中CXCR3、CXCL-10、CXCR4、CXCL-12、IL-4和IL-10的mRNA表达情况,并在一年中通过ELISA法评估了这些患者血清中的IL-10和CA-125含量。

结果

我们的结果显示,与良性卵巢囊肿相比,恶性卵巢组织中CXCR4的表达有升高趋势(P>0.05)。然而,与良性囊肿组织相比,恶性卵巢组织中SDF-1、IP-10、IL-4、CXCR3和IL-10的mRNA表达有降低趋势。除IL-4(P=0.01)和SDF-1(P=0.02)外,其他因素的数据无统计学意义。与良性囊肿患者相比,卵巢癌患者血清中IL-10浓度有升高趋势;然而,差异不显著。卵巢癌患者血清中CA-125浓度高于良性囊肿患者(P=0.05)。

结论

根据所得结果,我们推测恶性组织中SDF-1的低表达可能在卵巢肿瘤生长中起重要作用。然而,这一推测需要更多研究。患者血清中较高水平的CA125和IL-10可能表明,这些生物标志物的联合应用可用于区分卵巢癌患者和良性囊肿患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c52/4430884/a682e88e286a/ijms-40-225-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验